BCR (BCR Activator Of RhoGEF And GTPase)

The uniqueness of the case is the presence of an additional population of bonafide promonocytes in an otherwise typical case of Philadelphia-positive B-ALL expressing CD13 and CD33. This case underscores the importance of morphology and cytochemistry in detecting and confirming minor blast populations, which may manifest as the dominant or the only clone at relapse.

P2, N=64, Suspended, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

Additionally, the development of new therapeutic approaches is examined as a forward-looking tactic to produce more profound and long-lasting molecular responses which include immune-based therapies, combinatorial approaches, and promising third-generation TKIs. This review aims to improve patient outcomes and identify future avenues in CML research by combining new information with existing knowledge.

P1/2, N=180, Recruiting, Terns, Inc. | Phase classification: P1 --> P1/2 | N=100 --> 180 | Trial completion date: May 2026 --> May 2030 | Trial primary completion date: Nov 2025 --> Nov 2029

Significant clinical, hematological, and molecular responses were reported by the study. The drug was found to be easily tolerated, and any negative effects observed were effectively managed with appropriate care.

BM fibrosis is a critical factor influencing the response to TKIs in CML patients. Lower grades of fibrosis correlate with higher response rates and better clinical outcomes, suggesting the importance of early intervention and tailored treatment approaches based on fibrosis grading.

Receipt of payments from all competing companies occurs among a minority of oncologists, but a substantial minority for some drug classes. Oncologists who receive payments from multiple companies have different prescribing patterns than unpaid oncologists, suggesting that competing payments may not result in "balanced" influence.

P2, N=55, Enrolling by invitation, SWOG Cancer Research Network | Not yet recruiting --> Enrolling by invitation

Low-dose dasatinib is effective and tolerable in imatinib-resistant CML-CP, with nearly two-thirds achieving DMRs. Predictive biomarkers (T315I mutation, high ELTS risk, high baseline BCR-ABL1) can guide dose optimization.

KLC2-MT overexpression in BCR::ABL1-positive K562 and KU812 CML cells promoted cell proliferation and clonogenic potential, decreased imatinib sensitivity, and reduced apoptosis...KLC2-WT and KLC2-MT interacted with mothers against decapentaplegic homolog 2 (SMAD2); however, the latter impaired transforming growth factor-beta (TGF-β)-mediated SMAD2/3 activation while enhancing STAT3 phosphorylation. This study demonstrates the biological and functional importance of KLC2 mutation in CML cells, potentially enabling the development of better treatment strategies for CML patients carrying KLC2 mutations and providing enhanced understanding of the disease progression.

Although Gleevec has been transformative for CML, blast crisis CML remains relatively drug resistant...These data suggest that MSI2-HOXA9 acts, at least in part, by increasing expression of the mitochondrial polymerase POLRMT and augmenting mitochondrial function and basal respiration in blast crisis. Collectively, our findings demonstrate for the first time that translocations involving the stem and developmental signal MSI2 can be oncogenic and suggest that MSI, which we found to be a frequent partner for an array of translocations, could also be a driver mutation across solid cancers.

P2, N=124, Completed, Novartis Pharmaceuticals | Trial completion date: Jul 2026 --> Oct 2025 | Trial primary completion date: Jul 2026 --> Oct 2025 | Active, not recruiting --> Completed